10 Mid-Cap Stocks Insiders Are Selling Recently

3. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Number of Insiders Selling: 10

Market Capitalization: $5.152B

Ionis Pharamceuticals is a biotechnology company focused on discovering and developing RNA-targeted therapeutics. Currently, it has six marketed medicines and a pipeline in innovative therapies across areas of neurology, cardiology and rare diseases.

In December 2024, the U.S. Food and Drug Administration (FDA) greenlighted Tryngolza, an RNA-targeted therapy developed by Ionis for the treatment of familial chylomicronemia syndrome (FCS). Tryngolza is the first-ever FDA-approved treatment that significantly and substantially reduces triglyceride levels in adults with FCS and offers clinically meaningful reduction in AP events when used with an appropriate diet (≤20 grams of fat per day).

In January and February, 10 insiders, including CEO, CCO, and CBO sold approximately $5.12 million worth of Ionis Pharmaceuticals shares at an average price of around $32.54 per share. The stocks is now trading at $31.48, having lost 9.95% year-to-date.

As many as 18 analysts have “Buy” as the average rating for Ionis stock, while the stock price target is $62.0. David Lebowitz, an analyst from Citi, recently gave a “Buy” rating on the company’s shares, while the associated price target remains the same at $67.00.

Ionis is also one of the 12 Best Healthcare Stocks to Buy According to Analysts. Over the last 12 months, the company’s shares lost 37.51%.